Palmitoyl Tripeptide-1: Evidence, Mechanism & Safety

Palmitoyl Tripeptide-1 is one of the better-characterized cosmetic matrikines: a biomimetic, lipid-anchored delivery of the body's own GHK repair signal. It is best known as half of the Sederma blend Matrixyl 3000, and it shows up across serums, creams and eye products marketed for anti-aging.1 Its laboratory story is genuinely strong; its human story is real but small. This monograph separates the two.

This article is informational and editorial content for general education only. It is not medical advice, not a protocol to follow, and not a sourcing or buying guide. Palmitoyl Tripeptide-1 is a topical cosmetic ingredient — nothing here endorses injection, ingestion or any non-topical use. Use levels are reported strictly as seen in the literature and cosmetic-use surveys, for completeness, not as recommendations. Consult a qualified dermatologist before acting on anything below.

What is Palmitoyl Tripeptide-1 and how does it work?

Chemically, Palmitoyl Tripeptide-1 is the reaction product of palmitic acid and Tripeptide-1 (Gly-His-Lys, "GHK") — that is, N-palmitoyl-glycyl-L-histidyl-L-lysine, CAS 147732-56-7, molecular formula C₃₀H₅₄N₆O₅.5 You can confirm the structure and identifiers directly on the public chemistry record at PubChem CID 10231864. The 16-carbon saturated palmitoyl chain raises lipophilicity so the otherwise hydrophilic GHK can traverse the lipid-rich stratum corneum to reach the epidermis and dermis.1

The parent molecule is the real actor. GHK is a true endogenous human peptide found in plasma, saliva and urine, with plasma levels falling from about 200 ng/mL (roughly 10^-7 M) at age 20 to about 80 ng/mL by age 60 — paralleling the age-related decline in regenerative capacity.3 The GHK triplet exists within the alpha-2(I) chain of type I collagen and is proteolytically liberated at wound sites, acting as a "damage signal" that drives repair.34

As a matrikine, GHK and pal-GHK signal dermal fibroblasts to rebuild the extracellular matrix. They stimulate synthesis of collagen and glycosaminoglycans while simultaneously modulating the degradative machinery — upregulating collagen, dermatan sulfate, chondroitin sulfate and the small proteoglycan decorin, and regulating both matrix metalloproteinases (MMPs) and their inhibitors TIMP-1 and TIMP-2 — which positions the peptide as a master regulator of skin remodeling at non-toxic 1-10 nanomolar concentrations.3 The functional-medicine reading is restoration over force: the molecule does not whip fibroblasts so much as re-supply a youthful repair signal that fades with age. GHK also restores activity of genes in the TGF-beta pathway and broadly modulates a 450-gene fibroblast expression panel covering proliferation, migration and matrix remodeling.13

One mechanistic focus deserves a caveat. In normal human fibroblasts incubated 72 hours with vitamin C, palmitoyl peptides drove a dose-dependent increase in type I collagen plus de-novo synthesis of fibronectin and hyaluronic acid; pal-GHK alone gave a strong collagen signal at about 0.5 micromolar by tritiated-proline incorporation.1 The broader type III/IV-collagen and GAG breadth is best supported for the parent GHK matrikine rather than pal-GHK specifically, and is graded accordingly below.3 Note too that pal-GHK is sold as the non-copper amide; the GHK-Cu complex (Copper Tripeptide-1) is a related but distinct ingredient.2

What is the evidence by indication?

The human evidence is small and partly uncontrolled; the in-vitro and ex-vivo mechanism is solid. Every row below should be read with the sample sizes in mind.

The strongest single-peptide result is the periorbital study: 15 women aged 44 to 59 applied a cream with pal-GHK at about 3 ppm versus placebo twice daily for four weeks, and skin-replica image analysis showed statistically significant reductions in wrinkle length, depth and roughness while placebo had no effect.1 A second study applied pal-GHK at about 4 ppm to 23 healthy women and found a small but significant ~4% increase in skin thickness — meaningful given that aging skin thins about 6% per decade.1 Mechanistically, human abdominal biopsies irradiated with UVA for a week showed strong collagen degradation, while pal-GHK at about 5 ppm produced almost total preservation or renewal of dermal collagen, comparable in that single experiment to retinoic acid at 500 ppm — but this is ex-vivo, not a clinical photoprotection endpoint.1

Combination data muddy attribution. Two groups (n=24 and n=25) applied a 3% peptide-blend cream twice daily for two months with significant decreases in deep wrinkles and roughness and improved elasticity at day 56, and a 2023 Journal of Cosmetic Dermatology trial of a multi-peptide eye serum (4% Matrixyl 3000 plus Argireline and Eyeliss) reported wrinkle-count reductions near 32% by day 14 and 33% by day 28.16 The catch is that none of these can isolate pal-GHK's individual contribution, and the famous "45% deep-wrinkle reduction" marketing figure reflects wrinkle surface area and proprietary data, not an independent depth-measured RCT.7 Direct penetration evidence does exist: in a blinded study, 3D OrbiSIMS mass spectrometry detected the Matrixyl peptide within the stratum corneum at least ~13 cell layers deep — the first direct proof it crosses the barrier.7

What use levels appear in the literature?

Reported strictly as information, not a protocol — and the route is topical. Pal-GHK is not an injectable or oral therapeutic, and no such use is supported or studied.1 Study formulas used roughly 3 ppm in the 15-woman wrinkle study, about 4 ppm in the 23-woman thickness study, and about 5-6 ppm in the UVA ex-vivo work, with in-vitro activity near 0.5 micromolar.1 Industry use surveys report "typical use under 10 ppm," with finished products surveyed up to 0.9% in leave-on and 0.06% in rinse-off products, and INCI palmitoyl oligopeptide (GHK) reported up to 1%.2 Trial frequency ran twice daily for four weeks for the single peptide, extending to eight weeks or two months for combinations.1 Reconstitution does not apply — it is supplied as a cosmetic raw material, not a lyophilized injectable.1

How safe is Palmitoyl Tripeptide-1?

At cosmetic concentrations the profile is benign. The CIR Expert Panel concluded these ingredients, including Palmitoyl Tripeptide-1, are safe in cosmetics at present practices of use and concentration, noting that low use levels plus negative safety-test data obviate any concerns.2 No skin-irritation or sensitization signal was reported, and placebo-controlled pal-GHK studies reported no adverse local effects.1 No published genotoxicity, carcinogenicity or reproductive-toxicity data were located; the Panel judged the very low use concentrations sufficient to address those gaps.12

One caution deserves context. A palmitoyl oligopeptide (an elastin-derived sequence in that assay) enhanced angiogenesis in the chick chorio-allantoic membrane, the basis for a theoretical caution in active malignancy.1 However, the parent GHK matrikine itself downregulates metastatic cancer gene signatures, reactivates apoptosis genes and shows anti-cancer rather than pro-tumor expression patterns in vitro, and at sub-10-ppm topical use systemic exposure is expected to be negligible — so the concern is mechanistic and theoretical, not an observed clinical event.3 No drug interactions are established for topical cosmetic use; pregnancy and lactation are unstudied, so clinician consultation is prudent.2

What is the FDA and WADA status in 2026?

Legally this is settled territory. Palmitoyl Tripeptide-1 has no FDA drug approval and requires none for cosmetic use; under U.S. law a topical peptide product is regulated as a cosmetic so long as it makes only cosmetic claims such as cleansing, beautifying or altering appearance, while claims to treat disease or affect structure or function would reclassify it as a drug.8 Cosmetic ingredients other than color additives are not subject to FDA pre-market approval, and manufacturers bear safety responsibility.9 It is not an FDA-recognized injectable or compounded therapeutic — there is no 503A or 503B drug-compounding pathway for it, and "research-use" injectable vials sold online are unapproved and outside any legitimate clinical-use framework.8 The CIR has judged it safe in cosmetics.2

For athletes there is nothing to flag. Palmitoyl Tripeptide-1 is not on the WADA Prohibited List, and as a topical cosmetic matrikine it has no recognized anti-doping or ergogenic relevance.10 It is not a DEA-controlled substance.

Bottom line. Palmitoyl Tripeptide-1 is a biomimetic delivery of the endogenous GHK repair signal that genuinely stimulates dermal fibroblasts and protects collagen from UVA degradation in lab models. Its human clinical signal is real but modest and small-scale (Grade B): mild-to-moderate periorbital improvement and a small dermal-thickness gain in tiny vehicle-controlled studies, mostly in middle-aged women and usually within the Matrixyl 3000 blend, where individual contributions cannot be cleanly separated. Proven: good tolerability and a credible topical anti-aging effect. Hyped: retinol-equivalence, systemic uses, and single-peptide percentages pulled from combination or proprietary data. Key uncertainties are the absence of a large independent RCT and sparse human type IV-collagen and GAG endpoint data. Regulatorily it is a CIR-safe cosmetic ingredient — not an FDA drug, not WADA-banned.